Discover
llllllllll carboplatin / Generic mfg.; Tecentriq (atezolizumab) / RocheRoche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer (Roche Press Release) - Jul 13, 2020 - P3, N=1300; IMagyn050 (NCT03038100); Sponsor: Hoffmann-La Roche; "Roche...today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer....Data for the overall survival (OS) co-primary endpoint are currently immature and follow-up will continue until the next planned analysis. Results from IMagyn050 will be further evaluated in order to inform the Tecentriq gynaecologic development programme..."
llllllllll Tecentriq (atezolizumab) / RocheRoche's Tecentriq Disappoints In Ovarian Cancer Study (Scripintelligence) - Jul 13, 2020 - P3, N=1300; IMagyn050 (NCT03038100); Sponsor: Hoffmann-La Roche; "PD-1/PDL-1 inhibitors have not proved effective for ovarian cancer on their own or in combinations. Now Roche's Tecentriq, combined with the firm's blockbuster Avastin, has suffered a similar fate to Merck KGaA and Pfizer's Bavencio in failing to improve survival."
llllllllll pamiparib (BGB-290) / EMD SeronoBeiGene Announces Acceptance of a New Drug Application of Pamiparib in Ovarian Cancer in China (GlobeNewswire) - Jul 17, 2020 - "BeiGene, Ltd...announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a new drug application (NDA) of BeiGene’s investigational inhibitor of PARP1 and PARP2, pamiparib, for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more lines of chemotherapy....This NDA is supported by clinical results from a Phase 1/2 trial of pamiparib in patients with advanced ovarian cancer, fallopian cancer, and primary peritoneal cancer or advanced triple negative breast cancer (NCT03333915)."
llllllllll Tecentriq (atezolizumab) / RocheTecentriq misses mark in ovarian cancer trial (PharmaTimes) - Jul 14, 2020 - P3, N=1300; IMagyn050 (NCT03038100); Sponsor: Hoffmann-La Roche; "Roche and Genentech's Tecentriq (atezolizumab) has failed to hit its primary goal in a late stage trial involving patients with newly diagnosed advanced stage ovarian cancer...In the Phase III IMagyn050 study, the addition of Tecentriq to Avastin (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival..."
llllllllll Imfinzi (durvalumab) / AstraZeneca, BMS; Lynparza (olaparib) / Merck (MSD), AstraZenecaDurvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients. (clinicaltrials.gov) - Jul 16, 2020 - P3; N=1254; Recruiting; Sponsor: AstraZeneca; Trial primary completion date: Jan 2023 --> Jun 2023
llllllllll Keytruda (pembrolizumab) / Merck (MSD); Lenvima (lenvatinib) / Eisai, Merck (MSD)Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) (clinicaltrials.gov) - Jul 15, 2020 - P2; N=600; Recruiting; Sponsor: Merck Sharp & Dohme Corp.; Active, not recruiting --> Recruiting
